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Does Helicobacterpyloni Infection Contribute to
Gastroesophageal Reflux Disease?
Stuart Jon Spechler
The Centerfor Swallowing Disorders, Beth Israel Deaconess Medical Center
andHarvard Medical School, Boston, Massachusetts
Helicobacterpylori organisms that infect the stomach conceivably could con-
tribute to esophageal inflammation in patients with gastroesophageal reflux dis-
ease (GERD) through any ofat least three potential mechanisms: 1) by causing
an increase in gastric acid secretion; 2) by spreading to infect the gastric-type
columnar epithelium that occasionally can line the distal esophagus; and/or 3)
by secreting noxious bacterial products into the gastric juice. Studies regarding
these potential mechanisms are discussed in this report. Most investigations
have found no apparent association between H. pylori infection and reflux
esophagitis. Presently, infection with H. pylori does not appear to play an
important role in the pathogenesis ofGERD.
INTRODUCTION
The clinical approach to peptic ulcer disease has changed dramatically over the past
decade as evidence has accumulated to support a pivotal role for Helicobacter pylori
infection in the pathogenesis ofmostpeptic ulcerations in the stomach and duodenum [1].
Reflux esophagitis is also a common "peptic" disorder of the upper gastrointestinal tract
[2], and some studies have found an association between duodenal ulcer disease (a disor-
der that almost always is associated with H. pylori infection) and gastroesophageal reflux
disease (GERD)b [3]. On the basis ofthese observations, investigators have hypothesized
that H. pylori might play a pathogenetic role in GERD, and some have sought an associ-
ation between H. pylori infection and reflux esophagitis. However, a number ofstudies on
this issue have found no apparent association between the two disorders [4-7]. In a recent
prospective study of93 adult patients with GERD who had endoscopic examinations, for
example, no significant association was found between H. pylori status and the endo-
scopic grade of reflux esophagitis [4]. Two other recent endoscopic investigations, one
involving elderly patients [5] and one involving children [6], found no significant differ-
ences in the frequency of H. pylori infection among groups of patients with and those
without reflux esophagitis. Interestingly, one recent prospective study of consecutive
patients in a general endoscopy unit found that H. pylori infection was significantly less
common in patients with reflux esophagitis than in control patients without GERD, an
observation raising the intriguing (but unlikely) possibility that gastric infection with H.
pylori might even protect against the development of reflux esophagitis [7]. Despite the
results of these studies, it is conceivable that H. pylori could contribute to esophagitis in
GERD through any of at least three potential mechanisms: 1) H. pylori infection might
predispose to GERD by increasing gastric acid secretion; 2) H. pylori might cause
esophageal damage directly by infecting the gastric-type columnar epithelium that can
line the distal esophagus normally or as part ofBarrett's esophagus; or 3) H. pylori might
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cause esophageal damage indirectly through the action of noxious substances that are
secreted by the organism into the refluxed gastricjuice. Studies regarding these potential
mechanisms are discussed below.
H. PYLORI INFECTION AND GASTRIC ACID SECRETION
A number ofabnormalities in gastrin homeostasis have been described in individuals
who are infected with H. pylori. Compared to uninfected control subjects, for example,
fasting serum gastrin levels are approximately 40 percent higher in normal individuals
who have H. pylori infection [8]. Also, some H. pylori-positive individuals exhibit exag-
gerated gastrin release both in response to meals and to infusion ofgastrin releasing pep-
tide (GRP) [9, 10]. As a result ofthe latter abnormalities, postprandial and GRP-stimulat-
ed gastric acid output may be enhanced in H. pylori-positive individuals. The importance
of these abnormalities is not clear, however, because both basal and maximally-stimulat-
ed gastric acid outputs appear to be unaffected by H. pylori infection in otherwise healthy
subjects [8]. Furthermore, no significant differences in gastric acidity have been found
during 24-hour gastric pH monitoring studies in groups of normal individuals with and
withoutH. pylori infection [11]. In normal individuals, therefore, it seems unlikely thatH.
pylori infection contributes importantly to GERD through the organism's effects on gas-
tric acid secretion.
For decades, it has been known that patients who have duodenal ulcers are hyper-
secretors of gastric acid. Some of the observed abnormalities in gastric acid secretion,
such as elevated basal and GRP-stimulated acid outputs, can be reversed by eradication of
the H. pylori infection that accompanies most duodenal ulcers [10]. However, it is not
clear that H. pylori's effects on gastric acid secretion plays a role in the reflux esophagi-
tis that can be associated with duodenal ulcer disease. Indeed, it seems unlikely that H.
pylori-induced elevations ofgastric acid secretion contribute importantly to GERD in this
setting, because it has been found that treatment ofthe infection actually may precipitate
reflux esophagitis. In one recent study, for example, 17 (nine percent) of 190patients with
duodenal ulcerdisease developed reflux esophagitis within one to four years after theirH.
pylori infection was eradicated with antibiotics [12]. The authors speculated that the
development of reflux esophagitis might have been due to the withdrawal of antisecreto-
ry medications that were no longer necessary after cure of the peptic ulcer disease, or to
the weight gain that some patients experienced after eradication ofH. pylori infection.
Several years ago, investigators who knew ofthe phenomenon ofacid hypersecretion
in duodenal ulcer disease were surprised to find that the proton pump inhibitor omepra-
zole was more effective in controlling gastric acidity for patients with duodenal ulcers
than for healthy control subjects [13]. Given the same dose ofomeprazole, duodenal ulcer
patients (most ofwhom were infected with H. pylori) developedhigher median gastric pH
values than healthy controls. Other investigators found that omeprazole was also more
effective at raising the gastric pH in healthy subjects (without peptic ulcer disease) who
were infected with H. pylori than in theiruninfected counterparts [14]. These observations
suggested that H. pylori infection might somehow augment the acid inhibitory effects of
the proton pump inhibitor. In a recent study ofpatients with duodenal ulcer disease, gas-
tric acidity was measured by 24-hour pH monitoring both before and six weeks after
antibiotic therapy for H. pylori [15]. Eradication ofH. pylori had no significant effect on
the 24-hour gastric pH values for patients who were not taking omeprazole. In contrast,
treatment of the infection caused a dramatic decrease in the efficacy of omeprazole for
controlling gastric acidity. Before H. pylori eradication, the median 24-hour gastric pH
value during omeprazole treatment in 17 patients was 5.5. After antibiotic therapy, the
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median 24-hour gastric pH value for the same patients taking the same dose of omepra-
zole was 3.0. In terms of H+ ion concentration, the difference between a pH value of 5.5
and one of 3. 0 is more than 100-fold. This study shows that for some patients with duo-
denal ulcers, the eradication ofH. pylori infection renders proton pump inhibitor therapy
less effective in elevating the gastric pH. Similar results on proton pump inhibitor effica-
cy have been observed after the eradication ofH. pylori infection in subjects without pep-
tic ulcer disease [16]. Consequently, higher doses of proton pump inhibitors may be
required to control gastric acid secretion after antibiotic therapy aimed at H. pylori. For
patients with GERD who are treatedchronically with proton pump inhibitors, these obser-
vations suggest that eradication ofH. pylori has the potential to cause an exacerbation of
reflux esophagitis by decreasing the efficacy ofthe antisecretory drug. Presently, few pub-
lished data are available on this subject.
H. PYLORI INFECTION OF COLUMNAR EPITHELIUM IN THE ESOPHAGUS
To infect the stomach, H. pylori organisms first must adhere to gastric epithelial cells
[17]. Initially, this adherence is effected by specific H. pylori surface proteins (adhesins)
that bind glycoprotein, glycolipid and phospholipid receptors on the gastric cell mem-
branes [17,18]. H. pylori appears to be capable ofinfecting only columnar epithelia ofthe
gastric type [17]. Outside ofthe stomach, the organisms have been observed in islands of
gastric-type epithelia (heterotopic or metaplastic) that occasionally can be found in the
duodenum, the ileum, the rectum and the esophagus [19]. In addition to these isolated
islands of gastric-type epithelia, the mucosa of the gastric cardia normally can extend as
far as 2 cm above the esophagogastric junction to line the distal esophagus [20]. In this
situation, H. pylori infecting the cardia ofthe stomach can spread directly into the colum-
nar lining of the distal esophagus. The organisms cannot infect squamous cells, however,
and it seems unlikely that H. pylori in the cardiac epithelium contribute importantly to
inflammation in the squamous lining ofthe esophagus for patients with GERD. As noted
above, no significant association has been found between H. pylori infection ofthe stom-
ach and reflux esophagitis [4-7].
In some patients with GERD, the chronically inflamed squamous epithelium of the
esophagus is replaced by a metaplastic columnar lining that can have features ofboth gas-
tric and intestinal mucosae [21]. This condition is called Barrett's esophagus. The report-
ed frequency of H. pylori infection of the stomach in patients with Barrett's esophagus
ranges from 32 percent to 62 percent [22-28]. Among patients who have both Barrett's
esophagus and gastric infection with H. pylori, the organisms can be found frequently in
the metaplastic gastric-type epithelium that lines the distal esophagus [22-27]. However,
no study has reported results that suggest an important role for H. pylori infection in the
pathogenesis of Barrett's esophagus. Two studies have shown that gastric infection with
H. pylori is no more frequent in patients with Barrett's esophagus than in control patients
Table 1. Frequency ofH.pylori infection in patients with Barrett's esophagus and in age- and
sex-matched control patients without Barrett's esophagus.
Frequency ofH. pylori Frequency ofH. pylori
in patients in control patients
Study [Ref.] with Barrett's without Barrett's
Paull [22] 10/26 (38%) 11/26 (42%)
Blaser [28] 27/58 (47%) 26/58 (45%)
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(without Barrett's esophagus) who were matched for age and gender (Table 1).
Furthermore, H. pylori infection in patients with Barrett's esophagus does not appear to
correlate with the degree of esophageal inflammation as assessed by histologic or endo-
scopic examination [23, 25, 27].
By far the most common and important type of columnar lining found in Barrett's
esophagus is an aberrant intestinal-type of epithelium known as specialized intestinal
metaplasia [21]. This distinctive epithelium can be found in more than 90 percent of
patients who have long segments of columnar mucosa that extend to the mid- and proxi-
mal esophagus [29]. Furthermore, 10percent to 20percentofwhitepatients withoutendo-
scopic evidence ofBarrett's esophagus can be found to have short segments ofspecialized
intestinal metaplasia in biopsy specimens obtained at the esophagogastric junction [30,
31]. The latter condition has been called "shortsegment Barrett's esophagus" by some
authors. The precise pathogenetic factors that result in the development of specialized
intestinal metaplasia are not known. In the antrum and body of the stomach, intestinal
metaplasia is judged to be the result of chronic inflammation with gastric atrophy, and a
pathogenetic role for H. pylori infection has been proposed but not proved [32, 33]. H.
pylori infect only gastric-type epithelia, and so the organisms are not found in the spe-
cialized intestinal metaplasia thatcharacterizes Barrett's esophagus. As noted above, there
is no apparent association between Barrett's esophagus and H. pylori infection. Therefore,
it seems unlikely that the organisms contribute importantly to the development of spe-
cialized intestinal metaplasia in the esophagus. Few published data are available on the
role of H. pylori in the development of specialized intestinal metaplasia at the esopha-
gogastricjunction (short segment Barrett's esophagus), but at least one preliminary report
has concluded that H. pylori infection is not a risk factor for intestinal metaplasia in this
location [34].
NOXIOUS SUBSTANCES PRODUCED BY H. PYLORI
Table 2 lists some of the noxious substances produced by H. pylori. If these sub-
stances are secreted by the organisms into the gastricjuice, they might be carried into the
esophagus during episodes ofgastroesophageal reflux. It is conceivable that these agents
might injure the esophageal epithelium through a variety ofmechanisms. Toxic ammonia
is generated through the action of a urease enzyme that H. pylori produces in large quan-
tities [19]. The organism also produces a protease that can degrade protective mucous
[35], as well as lipase and phospholipase A that can attack mucosal lipids [36].
Furthermore, some strains ofH. pyloriproduce cytotoxins that can cause intracellular vac-
uolization in cultured cells [37]. In one recent study of 11 patients with GERD who were
infected with H. pylori, only five of the 11 patients had organisms that produced vacuo-
lating cytotoxin [37]. However, four of the five patients whose H. pylori produced the
cytotoxin had esophageal ulcerations, an observation suggesting thatcytotoxinproduction
could be a virulence factor forH. pylori. Further studies are needed to establish a role for
Table 2. Noxious substances produced by H.pylon.
Amonia
Protease
Lipase
Phospholipase A
Cytotoxins
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the reflux ofnoxious H. pylori products in the pathogenesis ofGERD. However, the lack
of any apparent association between reflux esophagitis and H. pylori infection argues
against an important pathogenetic role for the bacteria in GERD.
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